Showing results (221-230 of 247) with videos related to

Sort By:
Pageof 25
Alimentary Pharmacology & Therapeutics|March 18, 2022
Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD)Danielle Brandman, Marie Boyle, Stuart McPherson, et al.
Gastroenterology|April 19, 2019
Model to Calculate Harms and Benefits of Early vs Delayed Liver Transplantation for Patients With Alcohol-Associated HepatitisBrian P Lee, Sumeyye Samur, Ozden O Dalgic, et al.
Hepatology (Baltimore, Md.)|February 12, 2025
Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021Pojsakorn Danpanichkul, Kwanjit Duangsonk, Vincent L Chen, et al.
Hepatology (Baltimore, Md.)|November 4, 2025
AASLD/IDSA Practice Guideline on treatment of chronic hepatitis BMarc G Ghany, Calvin Q Pan, Anna S Lok, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 7, 2018
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and CirrhosisJoseph K Lim, Ann Marie Liapakis, Mitchell L Shiffman, et al.
Hepatology (Baltimore, Md.)|February 20, 2010
Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremiaMark H Kuniholm, Andrea Kovacs, Xiaojiang Gao, et al.
Hepatology (Baltimore, Md.)|November 7, 2021
Incidence and prediction of HBsAg seroclearance in a prospective multi-ethnic HBeAg-negative chronic hepatitis B cohortNorah A Terrault, Abdus S Wahed, Jordan J Feld, et al.
Transplantation|September 9, 2017
Prevalence and Predictors of Patient-Reported Long-term Mental and Physical Health After Donation in the Adult-to-Adult Living-Donor Liver Transplantation Cohort StudyMary Amanda Dew, Zeeshan Butt, Qian Liu, et al.
Gastroenterology|October 12, 2014
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantationMichael Charlton, Edward Gane, Michael P Manns, et al.
Gastroenterology|July 2, 2013
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infectionPatrick Marcellin, Curtis Cooper, Luis Balart, et al.
Pageof 25